Superiority of clinical American Joint Committee on Cancer T classification for perihilar cholangiocarcinoma
- PMID: 34717042
- DOI: 10.1002/jhbp.1066
Superiority of clinical American Joint Committee on Cancer T classification for perihilar cholangiocarcinoma
Abstract
Background: Clinical tumor staging is essential information for making a therapeutic decision in cancer. This study aimed to identify the optimal tumor classification system for predicting resectability and survival probability in perihilar cholangiocarcinoma.
Methods: Patients who were treated for perihilar cholangiocarcinoma between 2009 and 2018 were enrolled. Local tumor extension was staged radiologically according to a diameter-based classification system in addition to the AJCC, Blumgart, and Bismuth systems. Survival and resectability were compared between T subgroups, and the discriminability of the four systems was assessed with Harrell's concordance index (C-index).
Results: Among 702 study patients, 559 (80.0%) underwent laparotomy, 489 (70.0%) of whom underwent resection. The resectability significantly decreased for more advanced tumors in all systems (P < .001); the AJCC system had the greatest discriminability for resectability (area under the curve 0.721). Overall survival at 5 years was 69.9% for AJCC cT1, 45.8% for cT2, 31.8% for cT3, and 15.3% for cT4 tumors (cT1 vs cT2; P = .002, cT2 vs cT3; P = .008 and cT3 vs cT4; P < .001). The AJCC system had the largest C-index of 0.627.
Conclusions: The AJCC T system was the optimal classification system for predicting resectability and survival in perihilar cholangiocarcinoma.
Keywords: AJCC system; Bismuth system; Blumgart system; perihilar cholangiocarcinoma; tumor staging.
© 2021 Japanese Society of Hepato-Biliary-Pancreatic Surgery.
References
REFERENCES
-
- Ebata T, Mizuno T, Yokoyama Y, Igami T, Yamaguchi J, Onoe S, et al. Predictive performance of Blumgart T staging for perihilar cholangiocarcinoma in a Japanese center. J Hepatobiliary Pancreat Sci. 2020;27(3):132-40.
-
- Jarnagin WR, Fong Y, DeMatteo RP, Gonen M, Burke EC, Bodniewicz BJ, et al. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg. 2001;234(4):507-19. discussion 517-509.
-
- Kimura N, Young AL, Toyoki Y, Wyatt JI, Toogood GJ, Hidalgo E, et al. Radical operation for hilar cholangiocarcinoma in comparable Eastern and Western centers: outcome analysis and prognostic factors. Surgery. 2017;162(3):500-14.
-
- Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273-81.
-
- Amin MB, Edge S, Greene F, Byrd DR, Brookland RK, Washington MK, et al. AJCC Cancer Staging Manual, 8th edn. New York, NY: Springer International Publishing; 2017.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
